Valeo Pharma Inc. (VPHIF)
OTCMKTS
· Delayed Price · Currency is USD
0.0469
-0.0471 (-50.11%)
At close: Aug 29, 2024
Valeo Pharma Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | Oct '19 Oct 31, 2019 | 2016 - 2018 |
| Revenue | 53.38 | 53.91 | 27.75 | 13.56 | 7.47 | 6.58 | Upgrade
|
| Revenue Growth (YoY) | -0.17% | 94.31% | 104.65% | 81.49% | 13.58% | 50.09% | Upgrade
|
| Cost of Revenue | 41.36 | 39.33 | 19.23 | 9.41 | 6.09 | 5.18 | Upgrade
|
| Gross Profit | 12.02 | 14.58 | 8.52 | 4.14 | 1.38 | 1.4 | Upgrade
|
| Selling, General & Admin | 27.85 | 28.98 | 24.72 | 14.53 | 5.16 | 4.81 | Upgrade
|
| Operating Expenses | 28.23 | 29.85 | 25.67 | 15.53 | 5.63 | 5.14 | Upgrade
|
| Operating Income | -16.21 | -15.27 | -17.15 | -11.38 | -4.25 | -3.74 | Upgrade
|
| Interest Expense | -15.41 | -13.79 | -6.46 | -1.36 | -0.6 | -0.11 | Upgrade
|
| Interest & Investment Income | 3.73 | 3.75 | 0.17 | 0 | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1.92 | -0.82 | -1.26 | 0.11 | -0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.49 | 0.28 | 0.24 | -0.17 | 0.18 | 0.23 | Upgrade
|
| EBT Excluding Unusual Items | -29.32 | -25.85 | -24.46 | -12.8 | -4.67 | -3.62 | Upgrade
|
| Asset Writedown | -1.91 | -1.51 | -2.73 | -0.44 | -0.04 | - | Upgrade
|
| Other Unusual Items | -0.99 | -0.46 | 0.27 | -1 | -0.05 | - | Upgrade
|
| Pretax Income | -32.12 | -27.81 | -26.92 | -14.23 | -4.76 | -3.62 | Upgrade
|
| Income Tax Expense | - | - | -1.17 | - | - | - | Upgrade
|
| Net Income | -32.12 | -27.81 | -25.75 | -14.23 | -4.76 | -3.62 | Upgrade
|
| Net Income to Common | -32.12 | -27.81 | -25.75 | -14.23 | -4.76 | -3.62 | Upgrade
|
| Shares Outstanding (Basic) | 88 | 86 | 81 | 70 | 58 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 86 | 81 | 70 | 58 | 50 | Upgrade
|
| Shares Change (YoY) | 5.42% | 6.50% | 15.63% | 20.76% | 16.78% | 39.09% | Upgrade
|
| EPS (Basic) | -0.37 | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | Upgrade
|
| EPS (Diluted) | -0.37 | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | Upgrade
|
| Free Cash Flow | -4.02 | -16.17 | -28.86 | -13.22 | -5.36 | -2.33 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.19 | -0.36 | -0.19 | -0.09 | -0.05 | Upgrade
|
| Gross Margin | 22.51% | 27.05% | 30.70% | 30.56% | 18.49% | 21.30% | Upgrade
|
| Operating Margin | -30.37% | -28.32% | -61.80% | -83.96% | -56.85% | -56.82% | Upgrade
|
| Profit Margin | -60.18% | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | Upgrade
|
| Free Cash Flow Margin | -7.54% | -30.00% | -104.03% | -97.49% | -71.75% | -35.46% | Upgrade
|
| EBITDA | -14.1 | -13.03 | -16.1 | -10.98 | -4.01 | -3.64 | Upgrade
|
| EBITDA Margin | -26.41% | -24.17% | -58.03% | -80.95% | -53.64% | -55.36% | Upgrade
|
| D&A For EBITDA | 2.11 | 2.23 | 1.05 | 0.41 | 0.24 | 0.1 | Upgrade
|
| EBIT | -16.21 | -15.27 | -17.15 | -11.38 | -4.25 | -3.74 | Upgrade
|
| EBIT Margin | -30.37% | -28.32% | -61.80% | -83.96% | -56.85% | -56.82% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.